《BioRxiv,3月31日,HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-04-01
  • HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV

    Aleksandra Milewska, Ying Chi, Artur Szczepanski, Emilia Barreto-Duran, Kevin Liu, Dan Liu, Xiling Guo, Yiyue Ge, Jingxin Li, Lunbiao Cui, Marek Ochman, Maciej Urlik, Sylwia Rodziewicz-Motowidlo, Fengcai Zhu, Krzysztof Szczubialka, Maria Nowakowska, Krzysztof Pyrc

    doi: https://doi.org/10.1101/2020.03.29.014183

    Abstract

    The beginning of 2020 brought us information about the novel coronavirus emerging in China. Rapid research resulted in the characterization of the pathogen, which appeared to be a member of the SARS-like cluster, commonly seen in bats. Despite the global and local efforts, the virus escaped the healthcare measures and rapidly spread in China and later globally, officially causing a pandemic and global crisis in March 2020. At present, different scenarios are being written to contain the virus, but the development of novel anticoronavirals for all highly pathogenic coronaviruses remains the major challenge. Here, we describe the antiviral activity of previously developed by us HTCC compound (N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride), which may be used as potential inhibitor of currently circulating highly pathogenic coronaviruses - SARS-CoV-2 and MERS-CoV.

    *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.

  • 原文来源:https://www.biorxiv.org/content/10.1101/2020.03.29.014183v1
相关报告
  • 《3月31日_HTCC作为SARS-CoV-2和MERS-CoV的高效聚合物抑制剂》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-02
    • 1.时间:2020年3月31日 2.机构或团队:波兰雅盖隆大学、江苏省疾病预防控制中心、南京融康博生物科技有限公司、波兰西里西亚医科大学、波兰格但斯克大学、南京医科大学 3.事件概要: 中国和波兰的研究人员在bioRxiv预印版平台发表论文“HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV”,文章支持,目前,人们正在制定不同的方案来遏制SARS-CoV-2,但针对所有高致病性冠状病毒的新型抗冠状病毒药物的研发仍是主要挑战。因此,文章描述了该研究团队之前开发的HTCC化合物(N-(2-羟丙基)-3-三甲基氯化铵壳聚糖)对SARS-CoV-2和MERS的抗病毒活性,该化合物可作为这两种病毒潜在抑制剂。 *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用。 4.附件: 原文链接:https://www.biorxiv.org/content/10.1101/2020.03.29.014183v1
  • 《BioRxiv,3月31日,Fully human single-domain antibodies against SARS-CoV-2》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-01
    • Fully human single-domain antibodies against SARS-CoV-2 Yanling Wu, Cheng Li, Shuai Xia, Xiaolong Tian, Zhi Wang, Yu Kong, Chenjian Gu, Rong Zhang, Chao Tu, Youhua Xie, Lu Lu, Shibo Jiang, Tianlei Ying doi: https://doi.org/10.1101/2020.03.30.015990 Abstract The COVID-19 pandemic is spreading rapidly, highlighting the urgent need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. We describe here the development of a phage-displayed single-domain antibody library by grafting naive CDRs into framework regions of an identified human germline IGHV allele. This enabled the isolation of high-affinity single-domain antibodies of fully human origin. The panning using SARS-CoV-2 RBD and S1 as antigens resulted in the identification of antibodies targeting five types of neutralizing or non-neutralizing epitopes on SARS-CoV-2 RBD. These fully human single-domain antibodies bound specifically to SARS-CoV-2 RBD with subnanomolar to low nanomolar affinities. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.